Join us   Log in  

PHARMASPIRE - Volume 10, Issue 1, January-March, 2018

Pages: 13-22

Date of Publication: 14-Jun-2022

Print Article   Download XML  Download PDF

Development, optimization and evaluation of anti-tubercular drugs loaded pulmonary solid lipid nanoparticles for management of tuberculosis using Box-Behnken design

Author: Jagdeep Singh, Goutam Rath, Gazal Sharma, Amit Kumar Goyal

Category: Pharmaceutics


The main aim of the study is to develop, optimize and characterize the anti-tubercular drugs loaded solid lipid nanoparticles (SLNs) for pulmonary delivery. In this particular study, the SLNs were developed by modified microemulsification method using BoxBehnken design. The Box-Behnken design shows that the low lipid concentration (2.25%), low surfactant concentration (5 ml), and high homogenization speed (5000 rpm) are the effective factors to be considered for the present study. The optimized formulation shows low particle size (241.6 nm), optimum polydispersity index (0.122), and entrapment efficiency 61.28% for rifampicin, and 66.13% for isoniazid with good release characteristics. The spray drying of resultant SLNs showed good powder flow properties.

Keywords: Box-Behnken design, isoniazid, pulmonary drug delivery, rifampicin, solid lipid nanoparticles


1. Meena LS, Rajni. Survival mechanisms of pathogenic mycobacterium tuberculosis H37Rv. FEBS J 2010;277:2416-27.

2. Gomez JE, McKinney JD. M. Tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004;84:29-44.

3. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-55.

4. Jeong YJ, Lee KS. Pulmonary tuberculosis: Up-to-date imaging and management. Am J Roentgenol 2008;191:834-44.

5. Bhardwaj A, Kumar L, Narang RK, Murthy RS. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artif Cells Nanomed Biotechnol 2013;41:52-9.

6. El-Ridy MS, Yehia SA, Kassem MA, Mostafa DM, Nasr EA, Asfour MH, et al. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety. Drug Deliv 2015;22:21-36.

7. Takenaga M, Ohta Y, Tokura Y, Hamaguchi A, Igarashi R, Disratthakit A, et al. Lipid microsphere formulation containing rifampicin targets alveolar macrophages. Drug Deliv 2008;15:169-75.

8. Sung JC, Padilla DJ, Garcia-Contreras L, Verberkmoes JL, Durbin D, Peloquin CA, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009;26:1847-55.

9. Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother 2006;57:1146-52.

10. Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2001;48:431-4.

11. Mehta SK, Kaur G, Bhasin KK. Analysis of tween based microemulsion in the presence of TB drug rifampicin. Colloids Surf B Biointerfaces 2007;60:95-104.

12. Swathi G, Prasanthi N, Manikiran S, Ramarao N. Solid lipid nanoparticles: Colloidal carrier systems for drug delivery. Chem Inform 2012;43:1-16.

13. Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): Method, characterization and applications. Int Curr Pharm J 2012;1:384-93.

14. Jawahar N, Meyyanathan S, Reddy G, Sood S. Solid lipid nanoparticles for oral delivery of poorly soluble drugs. J Pharm Sci Res 2012;4:1848-55.

15. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. Eur J Pharm Biopharm 2014;86:7-22.

16. Singh H, Bhandari R, Kaur IP. Encapsulation of rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with isoniazid at acidic pH. Int J Pharm 2013;446:106-11.

17. Kaur R, Garg T, Das Gupta U, Gupta P, Rath G, Goyal AK, etal. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol 2016;44:182-7.